Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Justin Delange

Neurology Flagstaff, AZ Doctor of Osteopathy

NPI 1689923096 CMS profile 76795

1215 N Beaver St, Flagstaff, AZ 86001

Open in the dashboard

General payments

$5,440

84 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Delange of Flagstaff, AZ is reported in the CMS Open Payments database as having received $5,440 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $302 17
2024 General $61 3
2023 General $1,598 26
2022 General $518 22
2021 General $93 5
2020 General $42 3
2019 General $2,826 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Delange
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Justin Delange were reported at $302. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Justin Delange Neurology median Middle half National median
2019 $2,826 $474 $118–$2,177 $163
2020 $42 $367 $82–$2,309 $114
2021 $93 $438 $104–$2,547 $132
2022 $518 $442 $103–$2,388 $149
2023 $1,598 $464 $119–$2,312 $160
2024 $61 $468 $119–$2,323 $164
2025 $302 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,842 9 payments
  2. LivaNova USA, Inc. $1,178 6 payments
  3. AbbVie, Inc. $887 45 payments
  4. Genentech USA, Inc. $158 7 payments
  5. Impel Pharmaceuticals Inc. $67 3 payments
  6. Novartis Pharmaceuticals Corporation $59 3 payments
  7. Argenx US, Inc. $45 2 payments
  8. UCB, Inc. $37 1 payment
  9. Dexcom, Inc. $33 1 payment
  10. Allergan Inc. $30 2 payments
  11. Other $104 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,885 75 payments
  2. Consulting Fee $1,800 1 payment
  3. Travel and Lodging $1,730 7 payments
  4. Education $24 1 payment
Products named General payments · program years 2019–2025
  1. AIMOVIG $2,854 10 payments
  2. VNS Therapy $1,140 4 payments
  3. QULIPTA $496 23 payments
  4. UBRELVY $286 14 payments
  5. BOTOX $235 17 payments
  6. OCREVUS $158 7 payments
  7. Enspryng $92 4 payments
  8. KESIMPTA $47 2 payments
  9. VYVGART Hytrulo $45 2 payments
  10. Trudhesa $43 2 payments
  11. Other $285 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 66 drugs

Part D claims

2,960

Median for Neurology: 833

Drug cost

$895,331

Median for Neurology: $202,670

Branded share of claims

28.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Kesimpta Pen Ofatumumab Brand 22 $208,840
Austedo Deutetrabenazine Brand 17 $148,525
Aimovig Autoinjector Erenumab-Aooe Brand 134 $101,236
Ubrelvy Ubrogepant Brand 50 $65,800
Nurtec Odt Rimegepant Sulfate Brand 44 $62,584
Dimethyl Fumarate Generic 28 $54,721
Emgality Pen Galcanezumab-Gnlm Brand 56 $43,135
Qulipta Atogepant Brand 24 $38,554
Ajovy Autoinjector Fremanezumab-Vfrm Brand 24 $25,472
Rytary Carbidopa/Levodopa Brand 13 $16,631

The 10 drugs with the highest cost, of 66 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$132,649

Of which drugs: $66,290

Medicare patients

317

Average age 73

Services billed

14,427

190 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 52%
Depression 26%
Diabetes 22%
Osteoporosis 22%
Alzheimer's or dementia 21%
Chronic kidney disease 19%
Ischemic heart disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 25 13,600 $66,267

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYEPTI
  • Lundbeck LLC $25
$25 — —
OCREVUS
  • Genentech USA, Inc. $19
$19 — —
QULIPTA
  • AbbVie, Inc. $8
$8 24 —
BOTOX
  • AbbVie, Inc. $8
$8 — 13,600

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record